PharmaShots | Incisive News in 3 Shots

Subscribe Now

Stage IV NSCLC

AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at WCLC 2021

AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at...

September 13, 2021

AstraZeneca Reports Results of Imfinzi (durvalumab) & Tremelimumab in Global P-III MYSTIC Trial for Stage IV Non-Small Cell Lung Cancer (NSCLC)

AstraZeneca Reports Results of Imfinzi (durvalumab) & Tremelimumab in Global P-III MYSTIC Trial for Stage IV Non-Small Cell Lu...

November 19, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us